Please assess the completion status of the following clinical trial:

Trial Title: Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with classic SCID phenotype (\<400 CD3/ul or maternally engrafted and \<10% of normal PHA lymphoproliferative response). Genotypic identification is preferable, but not required.~* Patients must have an acceptable stem cell donor (HLA matched relative, 9 or 10/10 HLA-matched unrelated, or haplocompatible relative).~Exclusion Criteria:~* Patients with leaky SCID syndromes, Omenn's Syndrome, reticular dysgenesis, ADA deficiency~* Lansky score \<60%~* Patient with expected survival \<4 weeks (including disseminated CMV infection involving lungs and/or CNS)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- T-cell Graft Permissive SCID (Type: EXPERIMENTAL): Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only
- T-cell Graft Resistant SCID (Type: EXPERIMENTAL): Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).